ED2: COST-EFFECTIVENESS OF ACROMEGALY TREATMENTS  by Wilson, LS et al.
Abstracts 369
tients’ responses to MQOL that had been helpful in their
decision making and the interventions arising from that
process.
RESULTS: The total of 348 consultations took place dur-
ing the study period; 274 consultations had the MQOL
forms completed. This was accounted for 127 patients.
There were 46 male and 81 female with mean age of 59
years old (range 26–85). 66 patients (52%) attended the
clinic for the first time. Of these 66 new patients, 31
(47%) had a record of the MQOL on their subsequent vis-
its. Compared with the first visits, the results show the
quality of life had improved in every domain (i.e., physical
symptoms, physical wellbeing, psychological and existen-
tial domains) on their subsequent visits. The overall qual-
ity of life score in particular was significantly improved
during the follow-up visits (P  0.05). Considering the use
of the MQOL, 101 (37%) consultations had a record of
doctors’ comments on utilizing the quality of life informa-
tion and the majority (95%) indicated the MQOL as being
useful during consultations, particularly information re-
lated to physical symptoms, psychological and existential
domains.
CONCLUSIONS: The findings support the practicality of
quality of life assessment in clinical practice and its value
as an outcome measure and monitoring tool of palliative
care services in this population.
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OBJECTIVES: The clinical results of the metformin sub-
study of the United Kingdom Prospective Diabetes Study
(UKPDS) were combined with published cost data through
modeling techniques, allowing a cost-effectiveness analysis
of the management of obese type 2 diabetes patients with
either conventional therapy or intensive therapy with met-
formin from the NHS perspective.
METHODS: Occurrence of diabetes-related complications
were simulated using a Markov model. Probabilities for
complications were taken from the UKPDS, and costs were
retrieved from published sources. Total direct costs and
mortality over an 11-year period were determined for pa-
tients randomized to either conventional therapy or inten-
sive therapy with metformin. Incremental costs per life year
gained for metformin versus conventional therapy were cal-
culated. Extensive sensitivity analysis was performed.
RESULTS: Mean (SD) costs per patient over the 11 year fol-
low-up period (discounted at 5% per annum) were £4043
(10’987) and £3613 (12’122) for patients randomized to
either conventional or intensive therapy with metformin, re-
spectively. Intensive therapy with metformin led to a 0.21
life years gained (discounted at 5% p.a.), and therefore
dominated conventional therapy, with lower costs and in-
creased life expectancy. Outcomes were most sensitive to
variations in the acquisition cost of metformin. Changes in
event rates and costs related to myocardial infarction, renal
failure and stroke also had an important impact.
CONCLUSIONS: Within the limitations of the modeling
study, intensive therapy with metformin is cost saving and
improves life expectancy in obese type 2 diabetes in the
UK setting. These findings should be confirmed by the eco-
nomic study performed alongside the UKPDS.
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OBJECTIVES: Acromegaly is a chronic disease with in-
creased morbidity and mortality. For this and other pitu-
itary tumors, the treatment choice changes between surgi-
cal or medical. The new generation of somatostatin
analogues resulted in a recent challenge in attitude towards
the traditional dominant role of pituitary surgery, but costs
of medical treatment are a concern. We conducted a cost-
effectiveness analysis comparing surgical treatment alone
with combinations of surgical and medical treatments and
comparing new and old formulations of medical treatment.
METHODS: We evaluated retrospectively 53 patients
with acromegaly who underwent pituitary trans-sphenoid
surgery alone or in addition to medical therapy. Outcomes
were analyzed as person months spent in different health
state outcomes, defined according to Growth Hormone
and Insulin-like growth factor-I levels. We used a decision
analytic modeling approach and included cost per added
year in a cured health state and cost per life year saved
comparing surgery only with either the addition of medical
treatment to all those non cured, or to all post surgery pa-
tients.
RESULTS: Patients spent as much as 65% of time in non-
cured health states. The average annual cost of acromegaly
treatment was $8,700. The cost-effectiveness ratio of treat-
ing patients with microadenomas or macroadenomas and
persistent disease following surgery was $30,733 and
$35,892 respectively per added year spent in a cured state.
New somatostatin formulations had little effect on the
overall results. The cost per life year saved was approxi-
mately $32,000. The results were cost-effective over a
wide range of costs and outcomes.
CONCLUSION: Medical management of acromegaly is
cost-effective providing further justification for more ag-
gressive treatment of patients with persistently active post-
operative disease.
